The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 05, 2014

Filed:

Jul. 06, 2011
Applicants:

John J. Rossi, Alta Loma, CA (US);

Mark A. Behlke, Coralville, IA (US);

Dongho Kim, Los Angeles, CA (US);

Inventors:

John J. Rossi, Alta Loma, CA (US);

Mark A. Behlke, Coralville, IA (US);

Dongho Kim, Los Angeles, CA (US);

Assignees:

City of Hope, Duarte, CA (US);

Integrated DNA Technologies, Inc., Coralville, IA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07H 21/04 (2006.01); C12N 15/113 (2010.01); C12N 15/11 (2006.01);
U.S. Cl.
CPC ...
C12N 15/113 (2013.01); C12N 2310/14 (2013.01); C12N 15/111 (2013.01); C12N 2320/51 (2013.01); C12N 2310/33 (2013.01);
Abstract

The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded RNA ('dsRNA'), and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery.


Find Patent Forward Citations

Loading…